Identify women at high-risk with HPV 16/18 genotyping.
Women with genotypes HPV 16 and 18 are at the greatest risk of developing high-grade cervical lesions.1
Normal cytology doesn't always mean cancer free.
Up to one third of cervical cancers occur in screened women.2,3 Invasive cervical cancer occurs in women with normal Pap cytology.
View the evidence base for HPV genotyping.
The ATHENA trial shows that 1 in 10 women positive for HPV 16 and/or 18 had high-grade cervical disease that was missed by cytology.4
- Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072-1079.
- Leyden WA, Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst. 2005;97(9):675-683.
- Andrae B, Kemetli L, Sparén P, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.J Natl Cancer Inst. 2008;100(9):622-629.
- Wright TC Jr, Stoler MH, Sharma A, et al. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol. 2011;136(4):578-586.